Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: A pooled analysis

Current Medical Research and Opinion

Volumn 31, Issue 1, 2015, Pages 99-106

  Zeng, Zhengpei ^a   Choi, Dong Seop ^b   Mohan, Viswanathan ^c   Emser, Angela ^d   Siddiqui, Kamran ^e   Gong, Yan ^d   Patel, Sanjay ^f   Woerle, Hans Juergen ^d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Korea University College of Medicine   (South Korea)

^c MADRAS DIABETES RESEARCH FOUNDATION   (India)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Singapore Pte Ltd   (Singapore)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Asian patients; DPP 4 inhibitor; Linagliptin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASIAN; BODY MASS; BODY WEIGHT DISORDER; BREAST DISEASE; CONNECTIVE TISSUE DISEASE; DIET RESTRICTION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FASTING PLASMA GLUCOSE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MIDDLE AGED; MODERATE RENAL IMPAIRMENT; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; THORAX DISEASE; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; WEIGHT GAIN; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ETHNOLOGY; META ANALYSIS; METABOLISM; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LINAGLIPTIN; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84918840600     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.964856     Document Type: Article

References (37)

1. IDF Diabetes Atlas. 2011. Available at: www.idf.org/diabetesatlas/ [Last accessed 16 July 2013]
2. Ramachandran A, Snehalatha C, Vijay V. Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004;65:189-95
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
4. Kang HW, Kim DJ, Lee MS, et al. Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects. Diabetes Res Clin Pract 2005;69:180-7
5. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001;50:590-3
6. Chow FCC, Chan S-P, Hwu C-M, et al. Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: the Southeast Asia perspective. J Diabetes Investig 2012;3:481-9
7. Chan SP, Ji LN, Nitiyanant W, et al. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific - Real-Life Effectiveness and Care Patterns of Diabetes Management: the RECAP-DM study. Diabetes Res Clin Pract 2010;89:e30-2
8. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real- Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
9. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009;49(Suppl 1):S16-29
10. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43
11. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215
12. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
13. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
14. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-61
15. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
16. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-61
17. Efficacy and safety of 3 doses of BI1356 (linagliptin) in type 2 diabetes patients. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00328172?term=NCT00328172&rank=1 [Last accessed 9 January 2013]
18. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409-19
19. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348-57
20. Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebocontrolled trial. Clin Ther 2012;34:1909-19 e15
21. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10
22. Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 1145-54. doi:10.1111/ dom.12011. Epub 2012 Oct 1
23. Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:364-71
24. Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, welltolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:833-43
25. Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012;4:227-37
26. Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28:268-75
27. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16
28. Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:737-44
29. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41
30. Staimez LR, Weber MB, Ranjani H, et al. Evidence of reduced b-cell function in Asian Indians with mild dysglycemia. Diabetes Care 2013;36:2772-8
31. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-Analysis. Diabetologia 2013;56:696-708
32. Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011;94:217-24
33. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
34. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
35. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-74
36. Trajenta Summary of Product Characteristics. 19/11/2012. Available at: http://www.medicines.org.uk/emc/medicine/25000/spc [Last accessed 20 March 2013]
37. Gujral UP, Pradeepa R, Weber MB, et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 2013;1281:51-63